Rad Net, Inc. RDNT
We take great care to ensure that the data presented and summarized in this overview for RadNet, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RDNT
View all-
Black Rock Inc. New York, NY9.61MShares$558 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.3MShares$424 Million0.01% of portfolio
-
Beck Mack & Oliver LLC New York, NY3.28MShares$190 Million3.73% of portfolio
-
State Street Corp Boston, MA2.48MShares$144 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY2.32MShares$135 Million1.89% of portfolio
-
Allspring Global Investments Holdings, LLC1.69MShares$98.1 Million0.16% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD1.66MShares$96.3 Million0.05% of portfolio
-
Geode Capital Management, LLC Boston, MA1.6MShares$93.1 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA1.52MShares$88.3 Million0.02% of portfolio
-
Jb Capital Partners LP Armonk, NY1.47MShares$85.6 Million17.24% of portfolio
Latest Institutional Activity in RDNT
Top Purchases
Top Sells
About RDNT
RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of images in the field of mammography, as well as AI solutions for lung and prostate cancer. As of December 31, 2021, it owned and managed 347 centers in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1981 and is headquartered in Los Angeles, California.
Insider Transactions at RDNT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 10
2025
|
Laura Pastre Jacobs Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,699
+9.09%
|
-
|
|
Jun 10
2025
|
Lawrence L Levitt Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,699
+1.58%
|
-
|
|
Jun 10
2025
|
Gregory E. Spurlock Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,699
+33.78%
|
-
|
|
Jun 10
2025
|
David L Swartz Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,699
+1.5%
|
-
|
|
Jun 05
2025
|
Michael N Murdock EVP, Mergers and Acquisitions |
SELL
Open market or private sale
|
Direct |
11,132
-20.53%
|
$645,656
$58.05 P/Share
|
|
Jun 01
2025
|
Alma Gregory Sorenson EVP, Chief Science Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,436
+0.88%
|
-
|
|
May 23
2025
|
Alma Gregory Sorenson EVP, Chief Science Officer |
SELL
Open market or private sale
|
Direct |
55,000
-4.52%
|
$3,080,000
$56.48 P/Share
|
|
May 22
2025
|
Alma Gregory Sorenson EVP, Chief Science Officer |
SELL
Open market or private sale
|
Direct |
45,000
-3.57%
|
$2,565,000
$57.06 P/Share
|
|
May 16
2025
|
Lawrence L Levitt Director |
SELL
Open market or private sale
|
Direct |
5,000
-2.94%
|
$305,000
$61.09 P/Share
|
|
May 16
2025
|
Stephen M Forthuber Pres & COO-Eastern Operations |
SELL
Open market or private sale
|
Direct |
18,820
-3.4%
|
$1,129,200
$60.34 P/Share
|
|
May 15
2025
|
Norman R Hames Pres and COO-West Operations |
SELL
Open market or private sale
|
Indirect |
2,911
-10.47%
|
$174,660
$60.0 P/Share
|
|
May 15
2025
|
Norman R Hames Pres and COO-West Operations |
SELL
Open market or private sale
|
Direct |
5,536
-2.17%
|
$332,160
$60.0 P/Share
|
|
May 01
2025
|
Alma Gregory Sorenson EVP, Chief Science Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,232
+0.81%
|
-
|
|
Apr 04
2025
|
Mital Patel EVP of Fin Planning, CAO |
BUY
Exercise of conversion of derivative security
|
Direct |
50,340
+5.0%
|
$553,740
$11.93 P/Share
|
|
Mar 19
2025
|
Norman R Hames Pres and COO-West Operations |
SELL
Open market or private sale
|
Direct |
5,000
-0.98%
|
$250,000
$50.22 P/Share
|
|
Mar 18
2025
|
Norman R Hames Pres and COO-West Operations |
SELL
Open market or private sale
|
Direct |
5,000
-1.91%
|
$240,000
$48.25 P/Share
|
|
Mar 17
2025
|
Norman R Hames Pres and COO-West Operations |
SELL
Open market or private sale
|
Direct |
5,000
-1.87%
|
$245,000
$49.79 P/Share
|
|
Mar 10
2025
|
David Jeffrey Katz EVP and Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,423
+12.94%
|
-
|
|
Mar 07
2025
|
David L Swartz Director |
SELL
Open market or private sale
|
Direct |
25,000
-12.56%
|
$1,250,000
$50.84 P/Share
|
|
Mar 07
2025
|
Cornelis Wesdorp Pres & CEO, Digital Health |
SELL
Open market or private sale
|
Direct |
1,000
-1.75%
|
$50,000
$50.52 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 379K shares |
|---|---|
| Exercise of conversion of derivative security | 147K shares |
| Other acquisition or disposition | 500K shares |
| Bona fide gift | 260K shares |
|---|---|
| Open market or private sale | 309K shares |
| Other acquisition or disposition | 250K shares |